TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Gastrointestinal Safety Evaluation of Two Over the Counter Analgesics

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Body Mass Index: 18-30 kg/m\^2~* Body Weight 60-80 kg~* Participant with both a normal stomach and proximal duodenum mucosa as evidenced by endoscopic results~Exclusion Criteria:~* Participant with evidence of current/active, or a history of gastrointestinal disease~* Participant with a history of renal disease, pulmonary edema, cardiomyopathy, liver disease, intrinsic coagulation defects, bleeding diseases or anticoagulant therapy~* Participant with a history of using antacids, H2 receptor antagonists, proton pump inhibitors, or misoprostol more than twice a month or has used any of these medications within 1 week of Visit 1.~* Participant with a current or recurrent disease, within 12 months of Visit 1, that could affect the action, absorption, disposition, or excretion of the study treatments or evaluation of the clinical or laboratory tests

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- Paracetamol Tablet (Type: ACTIVE_COMPARATOR): Paracetamol 500 mg tablet, 2 tablets administered 4 times a day (QID) with water.
- Ibuprofen Tablet (Type: ACTIVE_COMPARATOR): Ibuprofen 400 mg tablet, 2 tablets administered three times a day (TID) with water
- Placebo Tablet (Type: PLACEBO_COMPARATOR): Placebo tablets, 2 tablets QID administered with water.
- Ibuprofen Capsule (Type: ACTIVE_COMPARATOR): Ibuprofen 400 mg liquid gel capsules, 2 tablets, TID administered with water

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Immunomodulatory Effect of Vitamin D in Allogenic Post-transplant

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* The patient should accomplish all the criteria to proceed to an allogeneic transplant~* The patient or their legal guardians should signed the informed consent approved by the Ethics Committees of Clinical Trials~Exclusion Criteria:~* Hypercalcemia ≥ 10.5 mg/dl~* Renal insufficiency with creatinine level ≥ 2 x upper limit of normal (1,1 mg/dl)~* Participation in others Clinical Trials in which the intervention may affect the result of the study.~* Patients receiving GVHD immunoprophylaxis with thymoglobuline or GVHD prophylaxis including in vitro or in vivo lymphocytes T depletion (anti-lymphocyte T globulin, ALG)~* Patients receiving a transplant from an haploidentical donor

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group 1: Control (Type: NO_INTERVENTION): Control group is composed by the first 50 patients included in the study. Those patients will not receive the treatment. Evaluations and follow-up will be the same as in the other groups.
- Group 2: 1000IU/day of Vitamine D (Type: EXPERIMENTAL): It is composed by the following 50 patients joining the study. They will take 1000 IU of vitamin D once a day.
- Group 3: 5000IU/day of Vitamine D (Type: EXPERIMENTAL): It is composed by the last 50 patients joining the study. They will take 5000 IU of vitamin D once a day.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Omega-3 and Therapy Study for Childhood Bipolar Disorder- Not Otherwise Specified

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: FACTORIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 7-14 years (boys and girls)~* Has a diagnosis of BP-NOS according to the LAMS definition. Criteria as follows:~* Clinically significant bipolar symptoms that do not meet DSM IV TR criteria for bipolar disorder I or bipolar disorder II~* Elated mood plus 2 or more associated symptoms from DSM IV TR or irritable mood plus 3 or more symptoms~* A change in functioning, and a minimum duration of 4 hours within a 24-hour period and at least 4 cumulative lifetime days meeting criteria~* Full scale IQ ≥ 70~* Child and one parent or other caregiver must be able to complete all assessment~* Child must be able to swallow capsules (training in swallowing will be offered)~* Parent and child must be willing to have blood drawn from child at two study assessments.~Exclusion Criteria:~* Major medical disorders (eg diabetes, epilepsy, metabolic disorder)~* Inability to communicate in English~* Lack of access via phone~* Autism~* Schizophrenia, or other psychotic states warranting anti-psychotic medication~* Active suicidal concern (e.g., I want to kill myself, a plan for suicide, or an attempt in the past month; however, passive suicidal ideation, such as I wish I were dead would not exclude)~* Three or more symptoms rated as marked or severe on the KDRS or KMRS~* Concurrent mental health intervention (pharmacotherapy and/or psychotherapy) in the past month.

- Gender: ALL
- Minimum Age: 7 Years
- Maximum Age: 14 Years
- Healthy Volunteers: f

Study Arms:
- Placebo Supplement and No PEP (Type: PLACEBO_COMPARATOR): Will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.
- Omega-3 and PEP (Type: EXPERIMENTAL): Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.~Psychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment.
- Omega-3 and No PEP (Type: EXPERIMENTAL): Omega-3 Supplementation will receive 1000 mg Ω3 (two 500 mg capsules, each containing 350 mg EPA: 50 mg DHA; 100 other Ω3)by mouth, two times daily.
- Placebo Supplement and PEP (Type: EXPERIMENTAL): Placebo Supplement will receive two capsules by mouth, two times daily matched for odor and appearance with the active intervention.~Psychoeducational Psychotherapy (PEP)Therapy sessions occur twice a week for up to 24 sessions of manualized treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Autologous Bone Marrow Stem Cell Therapy Combined With Psychological Therapy and Rehabilitation for Autism

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of autism according to the Diagnostic and Statistical Manual-V diagnostic criteria for autistic disorder~Exclusion Criteria:~* Epilepsy~* Hydrocephalus with ventricular drain~* Coagulation disorders~* Allergy to anesthetic agents~* Severe health conditions such as cancer, failure of heart, lung, liver or kidney~* Active infections~* Severe psychiatric disorders~* Rett syndrome~* Fragile X syndrome

- Gender: ALL
- Minimum Age: 3 Years
- Maximum Age: 7 Years
- Healthy Volunteers: t

Study Arms:
- Stem cell transplantation (Type: EXPERIMENTAL): Stem cell transplantation 2 intrathecal administrations of autologous bone marrow mononuclear cells at baseline and 6 months afterward
- Psychological therapy and rehabilitation (Type: EXPERIMENTAL): Psychological therapy Rehabilitation in 3 months

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Follow-on Protocol of Pitavastatin Versus Simvastatin in Patients With Hypercholesterolemia or Dyslipidemia and Coronary Heart Disease Risk Factors

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Completed NK-104-304 (NCT 00309738)~* Hypercholesterolemia or combined dyslipidemia~* 2 or more risk factors for coronary heart disease (CHD)~Exclusion Criteria:~* Withdrawn or terminated from NK-104-304 (00309738)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Pitavastatin 4 mg (Type: EXPERIMENTAL): Pitavastatin 4 mg once daily
- Simvastatin 40mg/80mg (Type: ACTIVE_COMPARATOR): Simvastatin 40 mg or 80 mg once daily

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of LY2928057 in Hemodialysis Participants

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Participants having end-stage renal disease (ESRD), have received an erythropoiesis stimulating agent (ESA) at least weekly for 2 weeks prior to screening, and have been receiving adequate maintenance hemodialysis (3 times weekly) for at least 12 weeks prior to screening (that is, an approximate Kt/V greater than 1.1 (K equals dialyzer clearance of urea, t equals dialysis duration time, V equals volume of distribution of urea, which is approximately equal to the participant's total body water) based on the clinical judgment of participant's nephrologist and investigator and who are willing to stop (Parts A and B) or reduce (Part C) their stable ESA dose from the week of randomization until completion of the 6-week treatment period (unless rescue therapy is needed)~* Have a hemoglobin value (taken prior to dialysis if taken on a dialysis day) greater than or equal to 9.5 grams per deciLiter (g/dL) and less than or equal to 12.5 g/dL at screening~* Have a body mass index (BMI) of 18.5 to 45 kilograms per square meter (kg/m\^2) inclusive at screening~* Have a transferrin saturation (TSat) greater than or equality to 15 percent and ferritin greater than 40 nanograms per milliliter (ng/mL) at screening~Exclusion Criteria:~* Any cause of anemia other than renal disease~* A history of hyporesponsiveness to ESA

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LY2928057 (No ESA) (Type: EXPERIMENTAL): Multiple doses of LY2928057 administered intravenously (IV) either once every 2 weeks (Q2W) or once per week (QW) for 6 weeks. Participants discontinued their personal physician-prescribed erythropoiesis stimulating agent (ESA) before treatment.
- LY2928057 (Reduced ESA) (Type: EXPERIMENTAL): Multiple doses of LY2928057 administered IV either Q2W or QW for 6 weeks. Participants reduced their personal physician-prescribed ESA dose before treatment.
- Placebo (No ESA) (Type: PLACEBO_COMPARATOR): Multiple doses of placebo administered IV either Q2W or QW for 6 weeks. Participants discontinued their personal physician-prescribed ESA dose before treatment.
- Placebo (Reduced ESA) (Type: PLACEBO_COMPARATOR): Multiple doses of placebo administered IV either Q2W or QW for 6 weeks. Participants reduced their personal physician-prescribed ESA dose before treatment.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of MCI-196 in Patients With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients whose fasting blood glucose levels during the observation period are between 130mg/dL and 200mg/dL.~* Patients whose HbA1c is 7.0% or above during the observation period.~Exclusion Criteria:~* Patients with serious cardiac, hepatic or renal complications.~* Patients with serious diabetic complications.~* Patients with complete biliary obstruction or ileus.~* Pregnant, lactating, and probably pregnant patients, and patients who can not agree to contraception.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- MCI-196 (Type: EXPERIMENTAL): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment Outcome in Early Diffuse Cutaneous Systemic Sclerosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Age \> 18 Skin thickening \< 3 years Immunosuppressant use \< 4 months Proximal skin involvement to face/neck, elbow or knee~Exclusion Criteria:~Previous use of more than 4 months of methotrexate, mycophenolate mofetil, cyclophosphamide or other immunosuppressive treatments~Previous use of immunosuppressant therapy other than methotrexate, mycophenolate mofetil or cyclophosphamide within previous months~Previous stem cell transplantation therapy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Methotrexate (Type: None): Patients treated with Methotrexate at the entry of the study.
- Mycophenolate Mofetil (Type: None): Patients treated with Mycophenolate Mofetil at the entry of the study.
- Cyclophosphamide (Type: None): Patients treated with Cyclophosphamide at the entry of the study
- No Immunosuppressant (Type: None): Patients without immunosuppressant treatment at the entry of the study

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study Assessing Immunogenicity and Safety of IC43 In Intensive Care Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female patients aged between 18 and 80 years~* Patients admitted to an ICU with a need for mechanical ventilation for more than 48 hours at visit 0~* At high risk for acquiring infection against P. aeruginosa at visit 0.~* Patients who, as determined by the investigator, have a high probability of survival for at least 48 hours.~* In females, either childbearing potential terminated by surgery or 1 year post menopausal, or a negative pregnancy test and the willingness of practicing a reliable methods of contraception~* Written informed consent or waiver according to the national regulations~Exclusion Criteria:~* Known use of any other investigational or non-registered drug within 30 days prior to IC43 vaccination at Visit 0~* Low severity of illness defined by an acute physiology score \< 8 at visit 0~* Patients \< 6 months post organ transplantation~* Severe thrombocytopenia or other coagulopathy which in the opinion of the investigator makes the patient unsuitable for intramuscular injection~* Pregnancy, lactation~* Persons who have been committed involuntarily to an institution, e.g. mental health facility or prison, will not participate in the study

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- IC43 100 mcg (Type: ACTIVE_COMPARATOR): IC43 100 mcg with Aluminum hydroxide
- IC43 200 mcg (Type: ACTIVE_COMPARATOR): IC43 200 mcg with Aluminum hydroxide
- IC43 100 mcg w/o (Type: ACTIVE_COMPARATOR): IC43 100 mcg without Aluminum hydroxide
- Placebo (Type: PLACEBO_COMPARATOR): phosphate-buffered saline solution containing 0,9 % NaCl and 400 mcg Aluminum hydroxide as an adjuvant

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Enfortumab Vedotin in Japanese Subjects With Locally Advanced or Metastatic Urothelial Carcinoma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subject must have histologically confirmed, locally advanced (TNM classification T3b and any N; or T and N2-3) or metastatic Transitional Cell Carcinoma of the Urothelium (TCCU) (i.e., cancer of the bladder, renal pelvis, ureter, or urethra). Subjects with Urothelial Carcinoma with squamous differentiation or mixed cell types are eligible.~* Subject must be able to submit a tumor tissue samples for Nectin-4 expression analysis at central laboratory.~* Subject must have failed at least one prior chemotherapy regimen for advanced disease. Urothelial and bladder cancer subjects are not required to have failed prior chemotherapy regimen if considered unfit for cisplatin-based chemotherapy.~* Subject must have measurable disease according to Response Evaluation Criteria in Solid Tumor (RECIST) (version 1.1).~* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.~Exclusion Criteria:~* Preexisting sensory neuropathy Grade ≥ 2.~* Preexisting motor neuropathy Grade ≥ 2.~* Uncontrolled central nervous system metastasis that requires active treatment.~* Any anticancer therapy within 14 days prior to the first dose of study drug.~* Subjects with pre-existing immunotherapy-related adverse events requiring high doses of systemic steroids are not eligible.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm A: Enfortumab vedotin 1.0 mg/kg (Type: EXPERIMENTAL): All subjects assigned will receive a single 30 minute intravenous infusion of enfortumab vedotin (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 28 days.
- Arm B: Enfortumab vedotin 1.25 mg/kg (Type: EXPERIMENTAL): All subjects assigned will receive a single 30 minute intravenous infusion of enfortumab vedotin (ASG-22CE) once weekly for 3 weeks of every 4 weeks (i.e., on Days 1, 8, and 15). A cycle is 28 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial Comparing the Efficacy and Safety of Insulin Degludec/Liraglutide and Insulin Degludec in Subjects With Type 2 Diabetes

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with type 2 diabetes~* HbA1c (glycosylated haemoglobin) 7.5-10.0% (both inclusive)~* Subjects on stable daily doses for at least 90 days prior to trial start of: Basal insulin (total daily basal insulin dose within the range of 20-40U in combination with: metformin (1500 mg or more or max. tolerated dose) or metformin (1500 mg or more or max. tolerated dose) and SU (sulfonylurea) (equal to or more than half of the max. approved dose according to local label) or metformin and glinides (equal to or more than half of the max. approved dose according to local label)~* BMI (Body Mass Index) more than or equal to 27 kg/m\^2~Exclusion Criteria:~* Treatment with glucagon like peptide-1 (GLP-1) receptor agonists (e.g. exenatide, liraglutide), dipeptidyl peptidase 4 (DPP-4) inhibitors and/or thiazolidinediones within 90 days prior to trial start~* Impaired liver function~* Impaired renal function~* Screening calcitonin equal to or above 50 ng/l~* Subjects with personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2)~* Cardiac disorder defined as: congestive heart failure (NYHA class III-IV), diagnosis of unstable angina pectoris, cerebral stroke and/or myocardial infarction within the last 52 weeks prior to trial start and/or planned coronary, carotid or peripheral artery revascularisation procedures~* Severe uncontrolled treated or untreated hypertension (systolic blood pressure equal to or above 180 mm Hg or diastolic blood pressure equal to or above 100 mm Hg)~* Acute treatment required proliferative retinopathy or maculopathy (macular oedema) according to physician's opinion~* History of chronic pancreatitis or idiopathic acute pancreatitis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDegLira + metformin (Type: EXPERIMENTAL): IDegLira was injected subcutaneously once daily for 26 weeks.
- IDeg + metformin (Type: EXPERIMENTAL): IDeg was injected subcutaneously once daily for 26 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete